📰 Nasdaq Mnkd News
Nasdaq Mnkd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Mnkd. Real-time updates on events, politics, business and more.
February 29, 2024
MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Wedbush issued their Q2 2024 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, February 28th. Wedbush analyst A. Argyrides forecasts that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. Wedbush currently has […]
February 28, 2024
MannKind Co. (NASDAQ:MNKD – Get Free Report) shares rose 10.6% during trading on Wednesday . The company traded as high as $4.26 and last traded at $4.18. Approximately 1,060,401 shares traded hands during trading, a decline of 56% from the average daily volume of 2,431,067 shares. The stock had previously closed at $3.78. Wall Street […]
February 24, 2024
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. A […]
February 24, 2024
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. Other institutional investors have also modified […]
February 15, 2024
MANNKIND ANNOUNCES ENROLLMENT GOAL COMPLETION OF INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING AFREZZA...
December 20, 2023
RVW Wealth LLC trimmed its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 30.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,151 shares of the biopharmaceutical company’s stock after selling 19,849 shares during the quarter. RVW Wealth […]
December 13, 2023
MannKind Co. (NASDAQ:MNKD – Get Free Report)’s share price shot up 5.4% on Wednesday . The company traded as high as $3.72 and last traded at $3.70. 578,595 shares traded hands during trading, a decline of 80% from the average session volume of 2,881,283 shares. The stock had previously closed at $3.51. Analyst Ratings Changes […]
November 8, 2023
MannKind (NASDAQ:MNKD – Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03, Briefing.com reports. The company had revenue of $51.20 million for the quarter, compared to the consensus estimate of $50.73 million. The company’s quarterly […]
November 1, 2023
MannKind Co. (NASDAQ:MNKD – Get Free Report) dropped 6.3% during mid-day trading on Wednesday . The stock traded as low as $4.01 and last traded at $4.02. Approximately 1,102,042 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 2,894,030 shares. The stock had previously closed at $4.29. Wall […]
October 13, 2023
Wedbush initiated coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a research report released on Monday morning, MarketBeat reports. The firm issued an outperform rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for MannKind’s Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($0.10) EPS, […]